Jin-Young Min1, Seung-Heon Shin2, Hyun Ja Kwon1, Yong Ju Jang3. 1. Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 2. Department of Otolaryngology, Catholic University of Daegu, School of Medicine, Daegu, South Korea. 3. Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: jangyj@amc.seoul.kr.
Abstract
BACKGROUND: The first critical step for bacterial infection is attachment of bacteria to the cell adhesion molecules of epithelial cells. The rhinovirus (RV)-induced increased expression of cell adhesion molecules including fibronectin (Fn) and carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) is closely related to the activation of nuclear factor-kappa B (NF-κB). Recent studies have demonstrated that Levocetirizine (LCT) has anti-inflammatory properties that are mediated by inhibitory effects on NF-κB in addition to classic antihistaminic effects. OBJECTIVE: To investigate the inhibitory effects of LCT on the RV-induced expression of Fn and CEACAMs in human nasal epithelial cells (HNECs) and identified the effects of LCT on secondary Staphylococcus aureus and Haemophilus influenzae adhesion to RV-infected HNECs. METHODS: Primary HNECs obtained from inferior turbinate mucosa were pretreated with 50 nM LCT 24 hours before RV-16 infection and for 48 hours thereafter. The expression levels of Fn and CEACAMs were assayed by real-time polymerase chain reaction (PCR) and Western blotting. Bacterial adhesion to cells was assessed by confocal microscopy. RESULTS: Fibronectin and CEACAM messenger RNA (mRNA) and protein levels in HNECs were significantly increased by RV-16 infection. Levocetirizine significantly reduced these increases in mRNA levels and protein expression of Fn and CEACAMs. Confocal microscopy showed that treatment with LCT significantly reduced the adhesion levels of S aureus and H influenza in RV-infected HNECs compared with RV-infected, untreated HNECs. CONCLUSION: These findings suggest that LCT inhibits the expression of Fn and CEACAMs and has the potential to prevent secondary bacterial infections in RV-infected HNECs by interfering with bacterial adhesion.
BACKGROUND: The first critical step for bacterial infection is attachment of bacteria to the cell adhesion molecules of epithelial cells. The rhinovirus (RV)-induced increased expression of cell adhesion molecules including fibronectin (Fn) and carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) is closely related to the activation of nuclear factor-kappa B (NF-κB). Recent studies have demonstrated that Levocetirizine (LCT) has anti-inflammatory properties that are mediated by inhibitory effects on NF-κB in addition to classic antihistaminic effects. OBJECTIVE: To investigate the inhibitory effects of LCT on the RV-induced expression of Fn and CEACAMs in human nasal epithelial cells (HNECs) and identified the effects of LCT on secondary Staphylococcus aureus and Haemophilus influenzae adhesion to RV-infected HNECs. METHODS: Primary HNECs obtained from inferior turbinate mucosa were pretreated with 50 nM LCT 24 hours before RV-16 infection and for 48 hours thereafter. The expression levels of Fn and CEACAMs were assayed by real-time polymerase chain reaction (PCR) and Western blotting. Bacterial adhesion to cells was assessed by confocal microscopy. RESULTS:Fibronectin and CEACAM messenger RNA (mRNA) and protein levels in HNECs were significantly increased by RV-16 infection. Levocetirizine significantly reduced these increases in mRNA levels and protein expression of Fn and CEACAMs. Confocal microscopy showed that treatment with LCT significantly reduced the adhesion levels of S aureus and H influenza in RV-infected HNECs compared with RV-infected, untreated HNECs. CONCLUSION: These findings suggest that LCT inhibits the expression of Fn and CEACAMs and has the potential to prevent secondary bacterial infections in RV-infected HNECs by interfering with bacterial adhesion.
Authors: Ara Jo; Tae Gyu Choi; Jung Yeon Han; Mark H Tabor; Narasaiah Kolliputi; Richard F Lockey; Seong H Cho Journal: Front Pharmacol Date: 2022-05-31 Impact factor: 5.988
Authors: Ji Heui Kim; You Sun Kim; Gye Song Cho; Nam Hee Kim; Chang Hoon Gong; Bong Jae Lee; Yong Ju Jang Journal: Allergy Asthma Immunol Res Date: 2015-05-26 Impact factor: 5.764
Authors: M Fedy Morgene; Elisabeth Botelho-Nevers; Florence Grattard; Sylvie Pillet; Philippe Berthelot; Bruno Pozzetto; Paul O Verhoeven Journal: Virulence Date: 2018 Impact factor: 5.882
Authors: Esther Klaile; Tilman E Klassert; Inka Scheffrahn; Mario M Müller; Annina Heinrich; Kerstin A Heyl; Hendrik Dienemann; Christiane Grünewald; Robert Bals; Bernhard B Singer; Hortense Slevogt Journal: Respir Res Date: 2013-08-14